Vyzulta  (U.S.N.L.M.)
Dosing 1 drop daily in the evening
Chem Specs latanoprostene bunod 0.024%
Quantities 5ml
Cost 260.49
Class nitric oxide-donating prostaglandin F2α analog
Action Increases trabecular meshwork and uveoscleral aqueous outflow.
Slightly better IOP control than latanoprost. (7 to 9 mmHg IOP reduction from
average baseline of 26.7 mmHg in one study).
Usage Indicated for reduction of IOP in open angle glaucoma or ocular hypertension.
Side Effects Increased pigmentation of the iris and periorbital tissue (eyelid). Possible
cystoid macular edema in pseudophakes and aphakes.
Contraindications Hypersensitivity to Vyzulta or any other ingredient in the product.
Avoid with active intraocular inflammation.
Pediatric use Avoid in patients aged 16 years and younger due potential safety concerns
related to increased pigmentation following long-term chronic use.
Pregnancy No available human data for the use of VYZULTA during pregnancy.
Causes miscarriage, abortion, and fetal harm in rabbits.
0.02% BAK preserved.  May be stored at room temperature for 2 months.
Nitric oxide (a free radical) increases trabecular outflow.
    N.L.M. DailyMed page for Trusopt          PDR page for Trusopt